Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Related Articles by Review for PubMed (Select 23086625)

1.

Prognostic implications of cumulative dosing in total therapy 3.

Barlogie B, Crowley J.

Blood. 2012 Oct 18;120(16):3383-5. doi: 10.1182/blood-2012-05-426809. No abstract available. Erratum in: Blood. 2013 Mar 7;121(10):1924.

2.

[Current aspects of treatment of multiple myeloma].

Tribalto M, Avvisati G, Cantonetti M, Catalano G, Giovangrossi P, Masi M, Petrucci MT, Venditti A, Papa G.

Ann Ital Med Int. 1988 Jul-Sep;3(3):193-202. Review. Italian. No abstract available.

PMID:
3152856
3.

Advances in treatment for relapses and refractory multiple myeloma.

Richards T, Weber D.

Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6. Review.

PMID:
20213220
4.

Novel agents for relapsed and/or refractory multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Review.

PMID:
20010168
5.

Lenalidomide in multiple myeloma: current role and future directions.

Zeldis JB, Knight RD, Jacques C, Tozer A, Bizzari JP.

Expert Opin Pharmacother. 2010 Apr;11(5):829-42. doi: 10.1517/14656561003645611. Review. Erratum in: Expert Opin Pharmacother. 2010 Sep;11(13):2273. Expert Opin Pharmacother. 2011 Mar;12(4):679.

PMID:
20210686
6.

Management of relapsed and relapsed refractory myeloma.

Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. Review.

PMID:
17996594
7.

Novel treatment approaches for patients with relapsed and refractory multiple myeloma.

Sinha R, Lonial S.

Curr Treat Options Oncol. 2006 May;7(3):246-57. Review.

PMID:
16615880
8.

Thalidomide in the treatment of multiple myeloma.

Kastritis E, Dimopoulos MA.

Best Pract Res Clin Haematol. 2007 Dec;20(4):681-99. Review.

PMID:
18070713
9.

Lenalidomide in multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Best Pract Res Clin Haematol. 2007 Dec;20(4):717-35. Review.

PMID:
18070715
10.

Treatment of relapsed and refractory myeloma.

Kaufman J, Gleason C, Lonial S.

Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5. Review.

PMID:
20425421
11.

Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Plosker GL.

Drugs. 2008;68(17):2535-51. doi: 10.2165/0003495-200868170-00008. Review.

PMID:
19016577
12.

The management of myelomatosis.

Galton DA, Brito-Babapulle F.

Eur J Haematol. 1987 Nov;39(5):385-98. Review. No abstract available.

PMID:
2446915
13.

Management of multiple myeloma.

Reizenstein P.

Leuk Res. 1989;13(3):199-201. Review. No abstract available.

PMID:
2651810
14.

[Results, failures and perspectives in therapy of multiple myeloma].

Bessmel'tsev SS, Abdulkadyrov KM.

Vopr Onkol. 2002;48(2):146-52. Review. Russian. No abstract available.

PMID:
12227061
15.

Management of multiple myeloma with bortezomib: experts review the data and debate the issues.

Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P.

Oncology. 2006;70(6):474-82. Epub 2007 Feb 2. Review.

PMID:
17283449
16.

[Multiple myeloma--advances in disease biology and implications for therapy].

Chou T.

Gan To Kagaku Ryoho. 2001 Sep;28(9):1206-12. Review. Japanese.

PMID:
11579631
17.

Advances in biology and treatment of multiple myeloma.

Ludwig H.

Ann Oncol. 2005;16 Suppl 2:ii106-12. Review. No abstract available.

18.

[Chemotherapy for multiple myeloma].

Togawa A.

Nihon Rinsho. 1995 Mar;53(3):647-52. Review. Japanese.

PMID:
7699899
19.

[Current therapy for multiple myeloma].

Swieboda-Sadlej A.

Pol Arch Med Wewn. 2005 Oct;114(4):1030-6. Review. Polish. No abstract available.

PMID:
16789532
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk